Lanteri Christophe, Hernández Vallejo Sandra Jimena, Salomon Lucas, Doucet Emilie Lucie, Godeheu Gérard, Torrens Yvette, Houades Vanessa, Tassin Jean-Pol
Centre National de la Recherche Scientifique, Unité Mixte de Recherche 7148, Collège de France.
J Neurosci. 2009 Jan 28;29(4):987-97. doi: 10.1523/JNEUROSCI.3315-08.2009.
Although nicotine is generally considered to be the main compound responsible for addictive properties of tobacco, experimental data indicate that nicotine does not exhibit all the characteristics of other substances of abuse. We recently showed that a pretreatment with mixed irreversible monoamine oxidases inhibitors (MAOIs), such as tranylcypromine, triggers a locomotor response to nicotine in mice and allows maintenance of behavioral sensitization to nicotine in rats. Moreover, we showed by microdialysis in mice that behavioral sensitization induced by compounds belonging to main groups of drugs of abuse, such as amphetamine, cocaine, morphine, or alcohol, was underlain by sensitization of noradrenergic and serotonergic neurons. Here, this neurochemical sensitization was tested after nicotine, tranylcypromine, or a mixture of both compounds. Data indicate that, whereas neither repeated nicotine nor repeated tranylcypromine alone has any effect by itself, a repeated treatment with a mixture of nicotine and tranylcypromine induces both behavioral sensitization and sensitization of noradrenergic and serotonergic neurons. The development of neurochemical and behavioral sensitizations is blocked by prazosin and SR46349B [(1Z,2E)-1-(2-fluoro-phenyl)-3-(4-hydroxyphenyl)-prop-2-en-one-O-(2-dimethylamino-ethyl)-oxime hemifumarate], two antagonists of alpha1b-adrenergic and 5-HT(2A) receptors, respectively, but not by SCH23390 [R(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride], a D(1) receptor antagonist. Finally, we found that pretreatments with WAY 100635 [N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl)cyclo-hexane carboxamide trihydrochloride], a 5-HT(1A) receptor antagonist, can also induce a behavioral and neurochemical sensitization to repeated nicotine. Complementary experiments with 8-OHDPAT (8-hydroxy-dipropylamino-tetralin), a 5-HT(1A) receptor agonist, and analysis of 5-HT(1A) receptors expression in the dorsal raphe nucleus after a tranylcypromine injection indicate that MAOIs contained in tobacco desensitize 5-HT(1A) autoreceptors to trigger the strong addictive properties of tobacco.
尽管尼古丁通常被认为是烟草成瘾特性的主要负责化合物,但实验数据表明尼古丁并不具备其他滥用物质的所有特征。我们最近发现,用混合不可逆单胺氧化酶抑制剂(MAOIs)如反苯环丙胺进行预处理,会引发小鼠对尼古丁的运动反应,并能使大鼠维持对尼古丁的行为敏化。此外,我们通过对小鼠的微透析表明,由主要滥用药物类别中的化合物如苯丙胺、可卡因、吗啡或酒精诱导的行为敏化,其基础是去甲肾上腺素能和5-羟色胺能神经元的敏化。在此,我们测试了尼古丁、反苯环丙胺或这两种化合物的混合物后的这种神经化学敏化。数据表明,单独重复给予尼古丁或反苯环丙胺本身均无任何作用,而重复给予尼古丁和反苯环丙胺的混合物会诱导行为敏化以及去甲肾上腺素能和5-羟色胺能神经元的敏化。神经化学和行为敏化的发展被哌唑嗪和SR46349B [(1Z,2E)-1-(2-氟苯基)-3-(4-羟基苯基)-丙-2-烯-1-酮-O-(2-二甲基氨基乙基)肟半富马酸盐]所阻断,它们分别是α1b-肾上腺素能受体和5-HT(2A)受体的拮抗剂,但未被D(1)受体拮抗剂SCH23390 [R(+)-7-氯-8-羟基-3-甲基-1-苯基-2,3,4,(5-四氢-1H-3-苯并氮杂卓盐酸盐]所阻断。最后,我们发现用5-HT(1A)受体拮抗剂WAY 100635 [N-[2-[4-(2-甲氧基苯基)-1-哌嗪基]乙基]-N-(2-吡啶基)环己烷甲酰胺三盐酸盐]进行预处理,也能诱导对重复给予尼古丁的行为和神经化学敏化。用5-HT(1A)受体激动剂8-OHDPAT(8-羟基-二丙基氨基-四氢萘)进行的补充实验,以及对反苯环丙胺注射后中缝背核中5-HT(1A)受体表达的分析表明,烟草中含有的MAOIs会使5-HT(1A)自身受体脱敏,从而引发烟草的强烈成瘾特性。